Bolt Biotherapeutics, Inc. Common Stock
BOLTBolt Biotherapeutics, Inc. is a biotechnology company focused on developing tumor-activated immunotherapies. They utilize their proprietary Amplify-They-Cell platform to design therapies that activate the immune system specifically within the tumor microenvironment, aiming to enhance cancer treatment efficacy while minimizing systemic side effects.
Company News
Bolt Biotherapeutics announced positive results from a Phase 1 study of its cancer immunotherapy BDC-3042, which showed favorable safety, biological activity, and signs of anti-tumor activity. The company is seeking a partner to advance the development of BDC-3042.
Bolt Biotherapeutics presented positive preclinical data for its next-generation cancer immunotherapy candidate BDC-4182 and key learnings from its Phase 1 trial of BDC-1001, suggesting that enhanced immune activation could lead to greater efficacy.
Bolt Biotherapeutics, Inc. is facing a securities fraud lawsuit alleging that the company made false and misleading statements about the effectiveness of its drug BDC-1001 in treating certain cancers, and overstated the commercial prospects of its drug pipeline.
Bolt Biotherapeutics, Inc. is facing a securities class action lawsuit due to allegedly making false and/or misleading statements about the effectiveness of its cancer treatment drug BDC-1001, which could lead to damages for investors.
A class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (BOLT) alleging that the company made materially false and misleading statements about the effectiveness of its product BDC-1001, overstating its clinical and commercial prospects.
